For many years surgery has been regarded as the gold standard for MIBC but now comparative trials, epidemiological findings and a meta-analysis of trials all show that outcomes… read more.
Intravesical therapy with chemotherapy or BCG is the recommended adjuvant treatment after TURBT to minimise the risk of recurrence. BCG shortages continue and BCG is not suitable for… read more.
The traditional surgical technique for TURBT involves piecemeal removal of the tumour whereas en bloc resection (ERBT) removes the whole tumour in one piece. Professor Jørgen Bjerggaard Jensen (Aarhus, Denmark)… read more.
The introduction of immunotherapy with immune checkpoint inhibitors has improved outcomes in trials. In this video Professor Morgan Roupret explains the current situation regarding immunotherapy and bladder cancer: This session… read more.
Lynch syndrome, an inherited cancer syndrome, has been prominently associated with colorectal cancer but other organs, including the urinary tract can also be affected. As a hereditary condition,… read more.
The median age for receiving a bladder cancer diagnosis is 73, and a significant number of those living with the disease are in their 70s and 80s. A longstanding stereotype… read more.
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) for the… read more.
Robot-assisted surgery used to perform bladder cancer removal and reconstruction enables patients to recover far more quickly and spend significantly (20 per cent) less time in hospital, concludes… read more.
Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancerinvestigators. The… read more.
Seagen Inc. and Astellas Pharma Inc. announced the FDA granted Padcev (enfortumab vedotin-ejfv) regular approval in the U.S., in addition to approving a new indication for adult patients… read more.
Genentech/Roche announced the FDA Oncologic Drugs Advisory Committee voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally… read more.
Gilead Sciences, Inc. announced that the FDA has granted accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC)… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
